Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Medical device

AstraZeneca AZ

AZ tweaks immuno-oncology trials as it chases lung cancer leaders

Toughens targets for durvalumab in NSCLC monotherapy and combination study

Allergan logo

Allergan plans to file oral uterine fibroid drug in US by year-end

Analysts predict treatment will reach blockbuster sales as phase III trials meet objectives

Biogen Idec building

Biogen proffers new data to support high-priced Spinraza

Trial demonstrates statistically-significant risk reduction in paediatric SMA for potential blockbuster drug

- PMLiVE

GSK targets COPD adherence with integrated inhaler sensors

Hopes real-time patient experience data will improve clinical trial engagement

- PMLiVE

Pfizer/Opko’s long-acting growth hormone misses mark in trial

Previously forecast as a blockbuster product, hGH-CTP fails to show significant change

Eli Lilly HQ

Lilly sinks as solanezumab fails again in Alzheimer’s

Amyloid-targeting drug showed no significant evidence of slow in cognitive decline

Webinar: Understanding Patient Willingness to Pay

What steps should pharma and medical device companies take to ensure they get their pricing strategy right in self-pay markets?

Research Partnership

AstraZeneca AZ

Trials of AZ’s durvalumab restart as FDA hold is relaxed

Bleeding side effects in two head and neck cancer studies not attributed to the PD-L1 inhibitor

Bristol-Myers Squibb (BMS) building

BMS teams up with Infinity Pharmaceuticals for Opdivo study

Will test dual therapy potential in targeting tumour resistance to checkpoint inhibitors

AstraZeneca AZ

AstraZeneca shaken by FDA partial hold on durvalumab trial

Aims to resume trial recruitment as soon as possible after bleeding side effects curb study

- PMLiVE

Rigel shaken after fostamatinib misses phase III trial target

Firm will still pursue early 2017 FDA approval for the autoimmune disease therapy

- PMLiVE

Clinical trials enter the genomic age

Looking at the factors driving this change and assessing the benefits

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links